- Home
- RPRX vs CNC Comparison
RPRX vs CNC Comparison
Compare RPRX & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | CNC |
|---|---|---|
| Founded | 1996 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 21.5B |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RPRX | CNC |
|---|---|---|
| Price | $49.86 | $38.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 17 |
| Target Price | ★ $50.00 | $41.94 |
| AVG Volume (30 Days) | 2.6M | ★ 4.6M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | $2,378,193,000.00 | ★ $194,777,000,000.00 |
| Revenue This Year | $38.30 | $8.31 |
| Revenue Next Year | $4.80 | $1.05 |
| P/E Ratio | $28.08 | ★ N/A |
| Revenue Growth | 5.06 | ★ 19.44 |
| 52 Week Low | $31.58 | $25.08 |
| 52 Week High | $49.99 | $63.42 |
Technical Indicators
Market Signals| Indicator | RPRX | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 67.58 | 57.83 |
| Support Level | $35.32 | $37.25 |
| Resistance Level | N/A | $39.61 |
| Average True Range (ATR) | 0.92 | 1.18 |
| MACD | 0.14 | 0.62 |
| Stochastic Oscillator | 94.63 | 87.32 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.